How CDSCO, FDA and EU MDR regulate a developmental-AI tool

A developmental-AI tool earns the right to support a child's care by clearing the same regulatory bars as any medical software — and by being honest about where its claims begin and end.

In short

A developmental-AI tool is regulated according to its intended use and risk class. In India, the CDSCO treats clinically-purposed Software as a Medical Device (SaMD) under the Medical Device Rules, 2017; in the United States, the FDA evaluates it as SaMD under the FD&C Act and its digital-health framework; in the European Union, the EU MDR (2017/745) classifies it via Rule 11 for software. A tool that only supports or screens — without making a diagnostic claim — may sit outside the SaMD boundary, but the moment it informs clinical decisions it falls squarely within these regimes.

How each regime treats developmental AI

• CDSCO (India) — Under the Medical Devices Rules, 2017, software with a medical purpose is risk-classified A–D. A developmental screening or assessment-support tool typically lands in Class A or B (low–moderate risk), requiring registration, a quality management system, and clinical evidence proportionate to its claims. Pinnacle's AbilityScore® is referenced as CDSCO Class B SaMD.
• FDA (United States) — The FDA assesses whether software meets the device definition, then applies risk-based oversight (510(k), De Novo, or enforcement discretion for lower-risk wellness or clinical-decision-support tools). Its Predetermined Change Control Plan framework is central for AI/ML tools that learn or update over time.
• EU MDR (European Union) — Standalone medical software is classified chiefly under Rule 11, which tends to push diagnostic and decision-driving software into Class IIa or higher, demanding a Notified Body conformity assessment, clinical evaluation, and post-market surveillance.

Across all three, the determining question is the claim: a tool that screens, monitors and routes a child to a clinician carries lighter obligations than one that diagnoses. Transparency about training data, performance, bias mitigation and human oversight is now expected everywhere.

Where a support tool sits

Many developmental-AI tools are deliberately scoped as screening and triage aids that never replace clinical judgement — they flag what merits a closer look and route families to qualified clinicians. This keeps them in a lower-risk tier while preserving child safety, because the diagnostic decision always rests with a human professional in a regulated setting.

The Pinnacle way

AbilityScore® is part of Pinnacle’s developmental assessment. Diagnosis, where needed, requires an appropriately qualified healthcare professional — never from an algorithm alone. The AbilityScore® is a clinician-administered structured assessment, registered as CDSCO Class B SaMD, built on 2.5 billion+ data points and 25 million+ therapy sessions, and protected by 16+ WIPO PCT patents with 12 validated studies behind it. Explore the Pinnacle network, understand what the AbilityScore® is and how it is administered, and see how it connects to speech therapy and family-facing care.

Trusted sources

WHO guidance on the classification of digital health interventions; CDSCO Medical Devices Rules framework for Software as a Medical Device; US FDA digital-health and SaMD oversight resources; EU MDR (Regulation 2017/745) software classification under Rule 11.

Next step — Evaluating a developmental-AI tool for clinical or institutional use? Contact the Pinnacle regulatory and clinical team to discuss SaMD scope, evidence and safe deployment.

This is general information, not a diagnosis — individual assessment and diagnosis require an appropriately qualified healthcare professional.